Aroa Biosurgery trial shows improved ulcer healing
- Aroa Biosurgery announced positive trial results for its Symphony medical product in treating diabetic foot ulcers.
- The company’s share price rose to $0.50 following the announcement.
- The clinical evidence is intended to support product differentiation, adoption, and US reimbursement requirements.
Aroa Biosurgery (ASX:ARX) released clinical trial results showing its Symphony biosaffold improved healing outcomes for patients with diabetic foot ulcers.
The randomised controlled trial evaluated 143 patients across 10 US sites to measure wound closure rates over a 12-week period.
“The Symphony trial demonstrates that combining a novel extracellular matrix biosaffold with high molecular weight hyaluronic acid can significantly improve wound healing when added to a good standard of care,” said Lead Investigator Dr David Armstrong.
Patients treated with Symphony achieved a 55% wound closure rate within 12 weeks compared to 35% in the standard care group, while average healing times fell from 73.2 days to 65.4 days.
The company stated that these clinical findings are expected to assist with expanding clinical adoption and meeting US reimbursement requirements.
Following the announcement, the Aroa Biosurgery share price was up at $0.50.
The company specialises in regenerative healing products derived from ovine extracellular matrix tissue.
The latest trial enrolled challenging diabetic foot ulcer cases classified as Wagner grade 1 or grade 2 across participating medical centres.
